Seeking Alpha

Questcor Pharmaceuticals (QCOR) soars 23.9% after reporting Q2 revenue and non-GAAP EPS of $46M...

Questcor Pharmaceuticals (QCOR) soars 23.9% after reporting Q2 revenue and non-GAAP EPS of $46M (+62% Y/Y) and $0.23, beating a consensus of $41.8M and $0.20. The company shipped 2,430 vials of its Acthar drug for treating multiple sclerosis, nephrotic syndrome, and infantile spasms, up 45% Y/Y. (PR) (transcript)

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs